Skip to Content
Søg Menu

Neoadjuvant melanoma: ESMO 2025 updates in 2 minutes

Associate Professor Marco Donia, MD, PhD, University of Copenhagen and Clinician-Scientist at Herlev Hospital, reviews the latest long-term data from ESMO 2025, highlighting why neoadjuvant treatment may outperform adjuvant therapy, and exploring emerging biomarkers and strategies.
Marco Donia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Marco Donia

Metastatic melanoma: ESMO 2025 updates in 2 minutes

/ Marco Donia
ESMO25Melanom Play the Video 2:34
Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostatacancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
ESMO25Blærecancer
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungecancer Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
ESMO25Blærecancer Play the Video 04:57
Jakob Lauritsen

ESMO 2025: De-eskaleret kemoterapi før vedligeholdelses-behandling med avelumab

/ Jakob Lauritsen
ESMO25Blærecancer Play the Video 01:15
Back to top